Impact of COVID-19 therapeutics on the development of post-infectious lung fibrosis
PCPF remains a relevant sequela in COVID-19 survivors. Remdesivir and baricitinib use were associated with a reduced and increased risk of PCPF, respectively. Although adjusted for multiple confounders, residual indication bias of each treatment cannot be completely excluded. Therefore, prospective studies are needed to validate these associations.
Authors
- Chi Young Kim (ORCID: https://orcid.org/0000-0003-3037-206X)
- Chul Hwan Park (ORCID: https://orcid.org/0000-0002-0004-9475)
- Yong Jun Choi (ORCID: https://orcid.org/0000-0002-6114-2059)
- Jae Hwa Cho (ORCID: https://orcid.org/0000-0002-3432-3997)
- Ji Ye Jung (ORCID: https://orcid.org/0000-0003-1589-4142)
- Min Kwang Byun (ORCID: https://orcid.org/0000-0003-1525-1745)
- Hye Jung Park (ORCID: https://orcid.org/0000-0002-1862-1003)
- Eun Hye Lee (ORCID: https://orcid.org/0000-0003-2570-3442)
- Ji Eun Nam
Institutions
- Yonsei University (KR)
- Severance Hospital (KR)
- Gangnam Severance Hospital (KR)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fmicb.2025.1677734
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health